Evermil 5mg Tablet

The human body shows undesired symptoms after taking Evermil 5mg Tablet. Usually, they disappear with time as the body adjusts to the medicine. It is advised to consult your doctor if these symptoms become unmanageable. Some of the side effects of Evermil Tablet are mentioned below:

• ​Difficulty breathing or swallowing
  
• Swelling of the face, lips, tongue, or throat
  
• Severe itching, red rash, or raised bumps
  
• Infection (chills, fever, or recurrent illness)
  
• Coughing, wheezing, or breathlessness
  
• Excessive thirst or abnormal urine output (too high or too low)
• Tiredness or fatigue
• Bleeding episodes
• Increased appetite with weight loss
  
• Elevated liver enzymes (alanine aminotransferase)
  
• High triglyceride levels in the blood
  
• Joint pain
  
• Pleural effusion (fluid around the lungs)
  
• Pulmonary edema (fluid in the lungs)
  
• Stomatitis (mouth inflammation or sores)
  
• Anemia (low red blood cell count)
  
• Low potassium levels in the blood
  
• Weight loss
  
• Changes in taste
• Rash or skin irritation
  
• Diarrhea
  
• Low blood platelets
  
• High blood sugar (increased glucose levels)
  
• Decreased appetite

• Mouth sores are the most common side effect, so doctors often recommend using a dexamethasone oral rinse (instead of alcohol-based mouthwash) to help prevent them.
• Infections can happen more easily while on treatment, so it’s important to watch for signs like fever or chills.
• Non-infectious pneumonitis, which is lung inflammation not caused by infection, is a unique and serious side effect of mTOR inhibitors; it may require lowering the dose or even stopping the medicine.
• Metabolic changes such as high blood sugar or cholesterol levels can occur, so regular monitoring is advised.
  
• It is advised to use effective birth control ways and avoid pregnancy during the treatment with the Evermil 5 mg Tablet.
• A person should avoid smoking while undergoing treatment with the Evermil 5 mg Tablet. Smoking may reduce the effectiveness of medicine.
• Monitor your blood sugar & pressure, kidney & liver function (KFT & LFT), and heart function at proper intervals after taking the Evermil 5 mg Tablet.
• Swelling of hands and lips and weight gain are some of the side effects observed after taking the Evermil 5 mg Tablet. To reduce them, the doctor may suggest some medication.
• Skin becomes extremely sensitive after taking the Evermil 5 mg Tablet. It is advised to cover your skin exposed to direct sun rays and use high SPF sunscreen before going out.
• It is advised to avoid taking analgesics/antacids (medicines used to neutralize the stomach acid) while taking the Evermil 5 mg Tablet, as it may reduce the effectiveness of the medicine.
• Keep your body hydrated, as diarrhea is one of the common side effects experienced after taking the Evermil 5 mg Tablet. Consult your doctor if it doesn't stop or if blood appears in your stools.
• In case you notice symptoms like blurred vision, difficulty breathing, cough & fever, and diarrhea while taking the Evermil 5 mg Tablet, consult your doctor immediately before these symptoms become severe.

• Bengueddache, S., Cook, M., Lehmann, S., Arroyo, D., Togni, M., Puricel, S., & Cook, S. (2024). Ten-year clinical outcomes of everolimus- and biolimus-eluting coronary stents vs. Everolimus-eluting bioresorbable vascular scaffolds—Insights from the EVERBIO-2 trial. Frontiers in Cardiovascular Medicine, 11(4), 1426348 -  https://pubmed.ncbi.nlm.nih.gov/39323753/
• Bingqi Zhuang, Chongning Zhong, Yuting Ma, Ao Wang, Hailian Quan, Lan Hong (2024). Innovative Therapeutic Strategies for Myocardial Infarction Across Various Stages: Non-Coding RNA and Stem Cells, International Journal of Molecular Sciences, 10.3390/ijms26010231, 26, 1, (231) - https://pmc.ncbi.nlm.nih.gov/articles/PMC11720039/
• De Simone, P., Precisi, A., Lai, Q., Ducci, J., Campani, D., Marchetti, P., & Gitto, S. (2024). Everolimus Mitigates the Risk of Hepatocellular Carcinoma Recurrence after Liver Transplantation. Cancers, 16(7), 1243 - https://pubmed.ncbi.nlm.nih.gov/38610921/
• Fort-Casamartina, E., Pernas, S., Otero, S., Mate, P., Gonzalo, N., Narváez, S., Rigo-Bonnin, R., Padró-Miquel, A., Teulé, À., Garcia del Muro, X., Peiró, I., Arribas, L., Esteve, A., Gonzalez, A., Rey, M., Clopés, A., Fontanals, S., & Muñoz, C. (2025). Everolimus Through Plasmatic Concentrations in Cancer Patients: Prospective Longitudinal Observational Multicentric Study (DIANA-1 Project). Journal of Clinical Medicine, 14(1), 145 - https://www.mdpi.com/2077-0383/14/1/145
• Gulati S, Tangen C, Ryan CW, et al. (2024) Adjuvant Everolimus in Non–Clear Cell Renal Cell Carcinoma: A Secondary Analysis of a Randomized Clinical Trial. JAMA Netw Open.7(8):e2425288 - https://pubmed.ncbi.nlm.nih.gov/39106067/
• Powles, T., Choueiri, T. K., Albiges, L., Peltola, K., de Velasco, G., Burotto, M., Suarez, C., Ghatalia, P., Iacovelli, R., Lam, E. T., Verzoni, E., Gümüş, M., Stadler, W. M., Kollmannsberger, C., Melichar, B., Venugopal, B., Gross‑Goupil, M., Poprach, A., De Santis, M., Rizzo, M., Shinde, R., Saretsky, T. L., He, L., Perini, R. F., & Vickery, D. (2025). Health‑related quality of life with belzutifan versus everolimus for advanced renal cell carcinoma (LITESPARK‑005): Patient‑reported outcomes from a randomized, open‑label, phase 3 trial. Lancet Oncology, 26(4), 491–502.
• Saliba F, Duvoux C, Dharancy S, Dumortier J, Calmus Y, Gugenheim J, Kamar N, Salamé E, Neau-Cransac M, Vanlemmens C, Durand F, Pageaux GP, Hardwigsen J, Benkhatar Y, Derquenne F, Conti F. (2025) Five-year outcomes in liver transplant patients receiving everolimus with or without a calcineurin inhibitor: Results from the CERTITUDE study. Liver Int. Nov;42(11):2513-2523.
• Taboada, R. G., Brito, A. B., Silva, A. L., Weschenfelder, R. F., & Riechelmann, R. P. (2024). The Efficacy of a Lower Dose of Everolimus in Patients with Advanced Neuroendocrine Tumors. Cancers, 16(22), 3773.